Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)
Citations Over TimeTop 10% of 2014 papers
Abstract
Potent, trans-2-(pyridin-3-yl)cyclopropanecarboxamide-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques. Multiple crystal structures were obtained of initial fragment leads, and this structural information was utilized to improve the biochemical and cell-based potency of the associated molecules. Many of the optimized compounds exhibited nanomolar antiproliferative activities against human tumor lines in in vitro cell culture experiments. In a key example, a fragment lead (13, KD = 51 μM) was elaborated into a potent NAMPT inhibitor (39, NAMPT IC50 = 0.0051 μM, A2780 cell culture IC50 = 0.000 49 μM) which demonstrated encouraging in vivo efficacy in an HT-1080 mouse xenograft tumor model.
Related Papers
- → Anticancer agent CHS-828 inhibits cellular synthesis of NAD(2008)116 cited
- → Quantitative analysis of the effects of nicotinamide phosphoribosyltransferase induction on the rates of NAD+ synthesis and breakdown in mammalian cells using stable isotope-labeling combined with mass spectrometry(2019)21 cited
- → Specific binding and uptake of extracellular nicotinamide in human leukemic k-562 cells(1993)23 cited
- Nicotinamide phosphoribosyltransferase inhibitors in cancer therapy:an advance(2012)
- → Abstract 1871: Targeting nicotinamide phosphoribosyltransferase (NAMPT) in cancer therapy.(2013)